Parameters | Total (n = 160) | Non-responders (n = 40) | Responders (n = 120) | P |
---|---|---|---|---|
Age | 62.35 ± 12.76 | 60.83 ± 11.47 | 62.86 ± 13.17 | 0.385 |
Male/Female(n/n) | 121/39 | 31/9 | 90/30 | 0.834 |
BMI | 24.03 ± 3.06 | 24.09 ± 3.47 | 24.01 ± 2.92 | 0.881 |
Hypertension(%) | 108(67.5%) | 24(60%) | 84(70%) | 0.165 |
Diabetes(%) | 40(25%) | 17(42.5%) | 23(19.17%) | 0.003* |
smoking(%) | 62(38.75%) | 21(52.5%) | 41(34.17%) | 0.039* |
Dyslipidemia(%) | 148(92.5%) | 36(92.31%) | 112(93.33%) | 0.732 |
ACEI/ARB (%) | 81(50.63%) | 19(47.5%) | 62(51.67%) | 0.716 |
CCB(%) | 38(23.75%) | 9(22.5%) | 29(24.17%) | 0.508 |
Statin(%) | 152(95%) | 36(92.31%) | 116(96.67%) | 0.2 |
PPI (%) | 48(30%) | 14(35%) | 34(28.5%) | 0.272 |
Nitrates | 65(40.625%) | 18(45%) | 47(39.17%) | 0.515 |
β-receptor blocker | 148(92.5%) | 36(90%) | 112(93.33%) | 0.488 |
Diuretics | 22(13.75%) | 6(15%) | 16(13.33%) | 0.791 |
Rivaroxaban | 12 (7.5%) | 4(10%) | 8(6.67%) | 0.488 |
Panax Notoginseng | 14(8.75%) | 5(8%) | 9(7.5%) | 0.332 |
Metal stent | 14 (8.75%) | 3(7.5%) | 11(9.17%) | 0.747 |
Drug-eluting stent | 146(91.25%) | 37(92.5%) | 109(90.83%) | 0.747 |
Infarct artery LAD | 115(71.88%) | 29(72.5%) | 86(71.67%) | 0.919 |
Infarct artery LCX | 108(67.5%) | 24(60%) | 84(70%) | 0.242 |
Infarct artery RCA | 135(84.38%) | 34(85%) | 101(84.17%) | 0.9 |
Infarct artery LM | 35(21.88%) | 8(20%) | 27(22.5%) | 0.74 |
clinical presentation | ||||
Angina | 25(15.63%) | 6(15%) | 19(15.83%) | 0.9 |
AMI | 116(72.5%) | 27(67.5%) | 89(74.16%) | 0.413 |